IL-7R agonists alone or in combination with checkpoint inhibitors have been reported to increase the number and function of anti-tumor T lymphocytes in peripheral blood of several cancer patient populations (e.g., checkpoint inhibitor [CPI]-naïve relapsed/refractory microsatellite stable colorectal cancer [MSS-CRC], CPI-naïve pancreatic cancer, and newly diagnosed high-grade gliomas after chemoradiation) [13,30,31]. Here, IL7R is linked to neoplasm.